Sunitinib Malate Schedule 4/2 vs. Sunitinib Malate Continuous Dosing As First-Line Therapy For Metastatic Renal Cell Cancer (RCC)

Clinical Trial ID NCT00267748

Rank	Title	Journal	Year	PubWeight™‹?›
1	Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma.	Br J Cancer	2014	2.26
2	Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma.	Eur Urol	2014	2.23
3	Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma.	Clin Cancer Res	2015	1.53
4	Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma.	Br J Cancer	2013	1.24
5	Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma.	Cancer Chemother Pharmacol	2014	1.04
6	Long-term Safety of Sunitinib in Metastatic Renal Cell Carcinoma.	Eur Urol	2015	0.92
7	Depth of remission is a prognostic factor for survival in patients with metastatic renal cell carcinoma.	Eur Urol	2015	0.84
8	Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations.	J Clin Oncol	2016	0.76
9	Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.	Eur Urol	2016	0.75